A comment was published on 10 June 2010, see Pharmaceuticals 2010, 3(6), 1887-1891.

Pharmaceuticals 2010, 3(1), 146-157; doi:10.3390/ph3010146

Impact of Glycosylation on Effector Functions of Therapeutic IgG

1,2,3,4email and 1,2,3,* email
1 INSERM UMRS 872, Paris, F-75006 France 2 Cordeliers Research Center, Université Pierre & Marie Curie, UMRS 872, Paris, F-75006, France 3 Université Paris-Descartes, UMRS 872, Paris, F-75006 France 4 Laboratoire français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France
Paper published on Special Issue “Monoclonal Antibody”, edited by Jagadeesh Bayry.
* Author to whom correspondence should be addressed.
Received: 15 December 2009; in revised form: 30 December 2009 / Accepted: 8 January 2010 / Published: 12 January 2010
(This article belongs to the Special Issue Monoclonal Antibody)
PDF Full-text Download PDF Full-Text [1675 KB, uploaded 13 January 2010 10:10 CET]
Abstract: Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the present review, we describe the main characteristics of IgG Fc glycosylation and some abnormalities of serum IgG glycosylation. We also discuss how glycosylation impacts on monoclonal antibodies (mAbs) and IVIg effector functions and how these molecules can be engineered. Several therapeutic antibodies have now been engineered to be no- or low-fucose antibodies and are currently tested in clinical trials. They exhibit an increased binding to activating FcγRIIIA and trigger a strong antibody-dependent cell cytotoxicity (ADCC) as compared to their highly-fucosylated counterparts. They represent a new generation of therapeutic antibodies that are likely to show a better clinical efficacy in patients, notably in cancer patients where cytotoxic antibodies are needed.
Keywords: antibody; Fc receptor; glycosylation; IgG

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Abès, R.; Teillaud, J.-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals 2010, 3, 146-157.

AMA Style

Abès R, Teillaud J-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals. 2010; 3(1):146-157.

Chicago/Turabian Style

Abès, Riad; Teillaud, Jean-Luc. 2010. "Impact of Glycosylation on Effector Functions of Therapeutic IgG." Pharmaceuticals 3, no. 1: 146-157.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert